Aytu BioPharma Q1 revenue beats estimates on higher EXXUA sales
Overview
U.S. CNS drugmaker's fiscal Q1 revenue rose 6.9%, beating analyst expectations
Adjusted EBITDA loss for fiscal Q1 narrowed, beating analyst estimates
Company to be acquired by Rosemont Pharmaceuticals for $2.70 per share in cash
Outlook
Company did not provide specific guidance for future quarters or the full year in its press release
Result Drivers
EXXUA GROWTH - Co said Q1 revenue growth was driven by higher EXXUA sales and a 33% sequential increase in prescriptions
ADHD PORTFOLIO DECLINE - Co attributed lower ADHD portfolio revenue to reduced promotional emphasis and generic competition
PEDIATRIC PORTFOLIO IMPROVEMENT - Co said pediatric portfolio revenue increased due to improved payer mix and lower returns
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $14.84 mln | $13.27 mln (3 Analysts) |
Q1 Net Loss | $3.88 mln | ||
Q1 Adjusted EBITDA | Beat | -$2.60 mln | -$2.93 mln (3 Analysts) |
Q1 Gross Profit | $9.44 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $7.00, about 293.3% above its November 13 closing price of $1.78
Reuters Recommended Reads
Nov 16 - ALX Oncology Q3 net loss per share narrows
Nov 16 - Prelude Therapeutics Q3 net loss narrows as expenses fall
Nov 16 - Invivyd Q3 revenue rises on PEMGARDA demand, loss per share less than expected
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)